Related Publications
07/25/12
FDA User Fee Act Full of Surprises for Pharma and Biotech
View all publications
FDA user fee reauthorization law expands fees to include generic and biosimilar applications, and includes a new emphasis on drug supply chain safety and incentives for development of new therapies.
Related News
05/15/13
Pharma Cos. Smell Victory In Push For Drug-Tracking System, Law360
Life Sciences partner Stephen Paul Mahinka is quoted.
05/08/13
Draft Senate Bill on Drug Compounding Does Not Go Far Enough, Stakeholders Say, BNA's Health Care Daily Report
FDA & Healthcare associate Lee H. Rosebush is quoted.
04/23/13
FDA's OxyContin Ruling May Spur New Battles Over Generics, Law360
View all news
FDA partner Rebecca Dandeker comments on the recent FDA ruling to block generic versions of the painkiller OxyContin.
- Represented pharmaceutical manufacturers regarding FDA, healthcare regulation, antitrust and state regulatory requirements relating to drug pricing, distribution and promotion programs.
- Litigated market exclusivity issues for a major pharmaceutical manufacturer concerning FDA approval of a generic version of its product.
- Negotiated a multistate consent settlement and related FDA enforcement action involving the promotion of prescription drugs and provision of pharmacists’ information services.
- Successfully represented a major pharmaceutical manufacturer in switching a combination drug from prescription to over-the-counter.
Copyright © 2013 by Morgan, Lewis & Bockius LLP. All Rights Reserved.
